| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Citius Pharmaceuticals Inc. | Mino-Lok | Catheter related blood stream infection (CRBSI) | Phase 3 | Data Released | Intravenous | N/A |
| Citius Pharmaceuticals Inc. | Halo-Lido - (CITI-002) | Hemorrhoids | Phase 2b | Trial Completed | Topical | N/A |
| Citius Pharmaceuticals Inc. | Mino-Lok | Catheter related blood stream infection (CRBSI) | Phase 3 | Data Released | Intravenous | N/A |
| Clarus Therapeutics Holdings Inc. | Once Daily (QD) oral TU | Male hypogonadism | Phase 2 | Oral | Endocrinology | |
| Clarus Therapeutics Holdings Inc. | CLAR-121 | Inflammatory breast disease (PDM) | Phase 2 | Intravenous | Oncology | |
| Clarus Therapeutics Holdings Inc. | Jatenzo | Chronic kidney disease | Phase 3 | Oral | N/A | |
| ClearPoint Neuro, Inc. | Upstaza | Gene therapy | BLA Filing | Trial Planned | Intracerebral | Genetic Disorder |
| Clearside Biomedical Inc. | Surabgene lomparvovec (sura-vec, ABBV-RGX-314) - (ATMOSPHERE) | Wet AMD | Phase 2/3 | Enrollment Conclusion | Subretinal injection | Opthalmic |